Reimbursement of Saxenda® (Liraglutide) 6mg/ml pre-filled pen 

vat-rates-product-information

As per Circular 02/23, the HSE has approved reimbursement for Liraglutide (Saxenda®) 6 mg/ml solution for injection in a pre-filled pen for weight management under Community Drug Schemes (GMS/DPS) from 1 January 2023.

This product is approved for reimbursement on the basis of managed access and approval can be confirmed through the ‘Secure Scheme Checker’ on the Pharmacy Suite under ‘Patient Specific Arrangements’.

Pharmacies can dispense and claim for Saxenda® electronically, using the product GMS code (37709), submitting in the usual manner with monthly claims.